News & Events

Q&A: Symbiosis: US FDA boost at Scottish aseptic viral vector plant

Colin MacKay, CEO of Symbiosis Pharmaceutical Services, recently took part in a Q&A interview with BioProcess Insider, discussing US Food and Drug Administration (FDA) approval and what it means for Symbiosis in terms of meeting industry demands now and post-Brexit.

The article provides insight into the significance of US FDA accreditation, the Innovate UK grant and the challenges Brexit poses for Symbiosis and other pharma companies.

In the interview, Colin explains: “The successful completion of our first FDA inspection earlier this year positions Symbiosis perfectly to support the global market, including US biopharma clients developing viral vector products for commercial markets in particular.”

You can read the full Q&A here, via BioProcess Insider.

Get In Touch.


By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.